Revista nº 813

Anticuerpos en la artritis reumatoide | Clavero López R, et al. Actual Med. 2021; 106(813): 157- 164 164 6. Anquetil F, Clavel C, Offer G, Serre G, Sebbag M. IgM and IgA rheumatoid factors purified from rheumatoid arthritis sera boost the Fc receptor- and complement-dependent effector functions of the disease-specific anti-citrulli- nated protein autoantibodies. J Immunol. 2015; 194(8): 3664–74. DOI: 10.4049/jimmunol.1402334 7. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheuma- toid arthritis. Arthritis Rheum. 1988; 31(3): 315–24. DOI: 10.1002/art.1780310302 8. Nielen MMJ, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MHMT, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: A study of serial measurements in blood donors. Arthritis Rheum. 2004; 50(2): 380–6. DOI: 10.1002/art.20018 9. Zendman AJW, van Venrooij WJ, Pruijn GJM. Use and sig- nificance of anti-CCP autoantibodies in rheumatoid ar- thritis. Rheumatology. 2006; 45(1): 20–5. DOI: 10.1093/ rheumatology/kei111 10. van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Toes RE, Huizinga TW. Antibodies to citrullinated pro- teins and differences in clinical progression of rheuma- toid arthritis. Arthritis Res Ther. 2005; 7(5): R949. DOI: 10.1186/ar1767 11. Derksen VFAM, Ajeganova S, Trouw LA, van der Helm- van Mil AHM, Hafström I, Huizinga TWJ, et al. Rheu- matoid arthritis phenotype at presentation differs de- pending on the number of autoantibodies present. Ann Rheum Dis. 2017; 76(4): 716–20. DOI: 10.1136/annrheu- mdis-2016-209794 12. van Dongen H, van Aken J, Lard LR, Visser K, Ronday HK, Hulsmans HMJ, et al. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: A dou- ble-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2007; 56(5): 1424–32. DOI: 10.1002/art.22525 13. Carbonell J, Cobo T, Balsa A, Descalzo MA CLSSG. The incidence of rheumatoid arthritis in Spain: results from a nationwide primary care registry. Rheumatol (Oxford). 2008; 47(7): 1088–92. DOI: 10.1093/rheumatology/ ken205 14. Enriconi dos Anjos LM, Pereira IA, d ‘Orsi E, Seaman AP, Burlingame RW, Morato EF. A comparative study of IgG second- and third-generation anti-cyclic citrullinated peptide (CCP) ELISAs and their combination with IgA third generation CCP ELISA for the diagnosis of rheuma- toid arthritis. Clin Rheumatol. 2009; 28(2): 153–8. DOI: 10.1007/s10067-008-0999-5 15. Nielsen SF, Bojesen SE, Schnohr P NB. Elevated rheu- matoid factor and long-term risk of rheumatoid arthritis: a prospective cohort study. BMJ. 2012; 345: e5244. DOI: 10.1136/bmj.e5244 Los autores/as de este artículo declaran no tener ningún tipo de conflicto de intereses respecto a lo expuesto en el presente trabajo. CONFLICTO DE INTERESES Si desea citar nuestro artículo: Clavero López R, Navarro Abad AI, Ruiz Herance M, Urra Ardanaz JM. Anti-péptidos citrulinados cíclicos y factor reumatoide en la Artritis Reumatoide. Actual Med. 2021; 106(813): 157- 164. DOI: 10.15568/am.2021.813. or02